[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-294312-105":59,"doc-detail-294312-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","2016-accp-annual-meeting-scientific-abstracts","2016 ACCP Annual Meeting Scientific Abstracts","","2016 ACCP Annual Meeting scientific abstracts compile multiple original research summaries across adult medicine, focusing on clinical outcomes and pharmacokinetic or pharmacodynamic effects of drug combinations and dosing strategies. Studies address QTc interval prolongation risk with concomitant levofloxacin and amiodarone, interaction effects of lansoprazole on neratinib exposure in healthy subjects, and anticoagulation assessment using aPTT and anti-Xa assays in obese non-acute coronary syndrome patients. Results emphasize measurable safety signals, quantitative pharmacokinetic changes, and study design details supporting retrospective and open-label analyses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/2016-accp-annual-meeting-scientific-abstracts/294312/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/2016-accp-annual-meeting-scientific-abstracts/294312.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-17",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is investigated in the levofloxacin and amiodarone QTc study?","Question",{"text":112,"@type":113},"The study examines how concomitant levofloxacin and amiodarone usage affects QTc interval prolongation and the occurrence rate of cardiac events in a real-world clinical setting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does lansoprazole affect neratinib exposure in healthy subjects?",{"text":117,"@type":113},"Lansoprazole reduced both the rate and extent of neratinib exposure, with lower Cmax and decreased AUC measures compared with neratinib alone.",{"name":119,"@type":110,"acceptedAnswer":120},"What methods are used to assess heparin anticoagulation adequacy in obese non-acute coronary syndrome patients?",{"text":121,"@type":113},"The abstract describes evaluating adequacy using both activated partial thromboplastin time (aPTT) and anti-Xa assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},294312,1789682249,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":129,"read_time":144,"preview_page_count":4},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","2016 ACCP ANNUAL MEETINGSCIENTIFIC ABSTRACTS  \n\n| ORIGINAL RESEARCH |\n| --- |\n| ADR/DRug InteRActIons |\n| 1E. Cardiac risk of concomitant levofloxacin with amiodarone.\u003Cbr>Mr. Benjamin Miao, PharmD Candidate1, Luigi Brunetti, PharmD, MPH2; (1)Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ; (2)Department of Pharmacy, Robert Wood Johnson University Hospital Somerset, Somerville, NJ\u003Cbr>INTRODUCTION: Levofloxacin, a commonly used quinolone antibiotic, and amiodarone, an antiarrhythmic agent, are both known to prolong the QT interval. Several case reports have been published describing the reality of the dangerous pro-arrhythmic characteristics due to the drug combination but no studies have been completed in a real-world, clinical setting.\u003Cbr>RESEARCH QUESTION OR HYPOTHESIS: The purpose of this study was to investigate the impact of the concomitant usage of levofloxacin and amiodarone on QT interval prolongation and the occurrence rate of cardiac events.\u003Cbr>STUDY DESIGN: A retrospective cohort study of all patients treated with levofloxacin and amiodarone when admitted to the medical center from January 1, 2012 to August 31, 2015. Only patients with available electrocardiograms before and after treatment were eligible for inclusion. Inclusion was limited to adult patients (>=18 years of age) . Patients on acute amiodarone therapy immediately upon admission were excluded from the study. Patients were stratified into two groups: concomitant usage of levofloxacin plus amiodarone and nonconcomitant usage of levofloxacin and amiodarone.\u003Cbr>METHODS: The primary outcome was change in QTc interval from baseline to post-treatment. The change in QTc interval was compared between\u003Cbr>RESULTS: A total of 107 patients were included in the preliminary analysis, 76 of which received concomitant levofloxacin and amiodarone. A mean change from baseline in QTc interval of 30.60 milliseconds(ms) for the concomitant group and-0.50 ms for the non-concomitant group. The mean difference between the two groups was 31.10 milliseconds (p\u003C0.001; 95% confidence interval, 18.52 ms, 43.69 ms) . There were no deaths in the study.\u003Cbr>CONCLUSION: The results from the analysis indicate that there is a statistically significant increase in QTc interval in patients given concomitant amiodarone and levofloxacin in comparison to patients given either medication alone.\u003Cbr>Presented at the ACCP Virtual Poster Symposium, May 2016, Best Poster Award, First Place\u003Cbr>2. Effects of multiple doses of lansoprazole on the pharmacokinetics of neratinib in healthy adult subjects.\u003Cbr>Kiana Keyvanjah, Pharm.D.1, Daniel DiPrimeo, M.S.1, Ai Li, Ph.D.1, Mohammad Obaidi, Ph.D.2, Dennis Swearingen, M.D.2, Alvin Wong, Pharm.D.1; (1)Puma Biotechnology Inc.; (2)Celerion\u003Cbr>INTRODUCTION: Most orally administered anticancer protein kinase inhibitors (PKIs) are weakly basic with pHdependent solubility. Acid-reducing agents increase gastric pH from 1.5-3 to 5-6, leading to reduced absorption of PKIs, including HER2-targeted tyrosine kinase inhibitors (TKIs) . Acid suppressive therapy is prevalent in cancer patients, and herein evaluated with neratinib. |\n\nAbstracts  \n2016 ACCP ANNUAL MEETING ABSTRACTS 1  \nAbstracts  \nRESEARCH QUESTION OR HYPOTHESIS: To evaluate the effects of lansoprazole, a proton-pump inhibitor, on the pharmacokinetics and safety of neratinib (Puma Biotechnology Inc.), a pan-HER TKI.  \nSTUDY DESIGN: Open-label, 2-period, fixed-sequence study (ClinicalTrials.gov: NCT02334501) .  \nMETHODS: Healthy adults received a single oral dose of neratinib 240 mg, followed by a washout period, followed by oral lansoprazole 30 mg once daily for 7 days and a single dose of neratinib 240 mg on Day 5. Pharmacokinetic sampling was performed for 72 hours after each neratinib dose. Plasma neratinib concentration-time data were analyzed using noncompartmental methods. A drug-drug interaction was concluded if 90% confidence intervals (CIs) for geometric ","cbCaivDtIB71cv38","https://ap.wps.com/l/cbCaivDtIB71cv38","pdf",2555112,297,"English","# Original Research\n## ADR/Drug Interactions\n### Cardiac risk of concomitant levofloxacin with amiodarone\n### Effects of multiple doses of lansoprazole on neratinib pharmacokinetics\n## Adult Medicine\n### Assessment of heparin anticoagulation adequacy in obese non-acute coronary syndrome patients","[{\"question\":\"What is investigated in the levofloxacin and amiodarone QTc study?\",\"answer\":\"The study examines how concomitant levofloxacin and amiodarone usage affects QTc interval prolongation and the occurrence rate of cardiac events in a real-world clinical setting.\"},{\"question\":\"How does lansoprazole affect neratinib exposure in healthy subjects?\",\"answer\":\"Lansoprazole reduced both the rate and extent of neratinib exposure, with lower Cmax and decreased AUC measures compared with neratinib alone.\"},{\"question\":\"What methods are used to assess heparin anticoagulation adequacy in obese non-acute coronary syndrome patients?\",\"answer\":\"The abstract describes evaluating adequacy using both activated partial thromboplastin time (aPTT) and anti-Xa assays.\"}]","2016 ACCP Annual Meeting Scientific Abstracts | PDF",748]